-
Talquetamab: Exploring its Role in Cancer Therapy and Ongoing Research(Post)
Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It
CD28: Amplifying T Cell Responses for Better Tumor Clearance(Post)The CD28 molecule plays a crucial role in amplifying T cell activation, which is critical for mounting effective immune responses against tumors. By engaging with co-stimulatory molecules
Anti-Angiogenics Do Not Starve Tumours. They Open Them.(Post)Anti-angiogenic therapy does not work by starving tumours, and the trials that assumed it did are the reason the field spent a decade disappointed. Cutting off the blood supply was the original pitch
HERV-K group of endogenous retroviruses and cancer(Post)In 2006, upon completion of the Human Genome Project, it was discovered that nearly 8% of the human genome is made up of viral DNA. These viral remnants are composed of ancient germl
Coronavirus Assays(Page)Coronavirus Assays | SARS-CoV-2 ELISA, Multiplex, Rapid & PCR | Assay Genie
Adenosine Axis — CD39, CD73 and A2A Receptors(Page) B7-H4: A New Frontier in Immune Checkpoint Inhibition(Post)The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Cleaved Caspase-3 and Apoptosis(Post)Cell Death · BiomarkersCleaved Caspase-3: Activation, Function and Detection in ApoptosisCaspase-3 sits at the point where apoptotic signalling becomes irreversible. It is made as an inactive proenzym
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
Daratumumab: Advancing Research in Multiple Myeloma and Beyond(Post)Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
IgA Test – Normal Ranges, Results & What They Mean(Post)Clinical · Immunology Guide IgA Test: Normal Ranges, Results & What They Mean [2026] What the immunoglobulin A blood test measures, how result
Assay Genie Mission(Page)Assay Genie Mission | Making Scientists Smile
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment(Post)Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
Carlumab: Exploring Its Mechanism, Clinical Potential, and Research Biosimilars(Post)Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress
Abituzumab: Understanding Its Role in Cancer and Fibrosis Research(Post)Quick Facts About AbituzumabWhat is Abituzumab?Abituzumab is a monoclonal antibody that targets αv-integrins, playing a role in cancer treatment and fibrotic diseases.What is the mechani
Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
T-Cell Co-Stimulation and Agonist Checkpoint Signalling Explained(Post)Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro
Targeted Protein Degradation: The Next Frontier in Oncology Drug Discovery(Post)For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d